Wall Street analysts expect Spring Bank Pharma (NASDAQ:SBPH) to report earnings per share (EPS) of ($0.47) for the current quarter, Zacks reports. Zero analysts have issued estimates for Spring Bank Pharma’s earnings. Spring Bank Pharma posted earnings per share of ($0.54) during the same quarter last year, which indicates a positive year-over-year growth rate of 13%. The business is scheduled to issue its next earnings results on Monday, July 30th.
According to Zacks, analysts expect that Spring Bank Pharma will report full-year earnings of ($1.82) per share for the current fiscal year, with EPS estimates ranging from ($1.87) to ($1.78). For the next financial year, analysts forecast that the company will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.94) to ($2.03). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Spring Bank Pharma.
Spring Bank Pharma (NASDAQ:SBPH) last posted its quarterly earnings results on Friday, April 27th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.15.
Spring Bank Pharma traded down $0.42, reaching $11.76, during trading on Thursday, MarketBeat Ratings reports. 120 shares of the stock were exchanged, compared to its average volume of 95,453. Spring Bank Pharma has a twelve month low of $10.81 and a twelve month high of $18.93. The company has a market cap of $163.03 million, a P/E ratio of -6.29 and a beta of -0.37.
A number of institutional investors and hedge funds have recently modified their holdings of SBPH. BVF Inc. IL grew its holdings in shares of Spring Bank Pharma by 26.2% in the fourth quarter. BVF Inc. IL now owns 823,474 shares of the company’s stock valued at $11,076,000 after acquiring an additional 170,798 shares in the last quarter. Millennium Management LLC bought a new position in shares of Spring Bank Pharma in the fourth quarter valued at approximately $676,000. Morse Asset Management Inc grew its holdings in shares of Spring Bank Pharma by 12.9% in the first quarter. Morse Asset Management Inc now owns 165,775 shares of the company’s stock valued at $2,492,000 after acquiring an additional 18,900 shares in the last quarter. AXA grew its holdings in shares of Spring Bank Pharma by 7.6% in the fourth quarter. AXA now owns 266,585 shares of the company’s stock valued at $3,583,000 after acquiring an additional 18,859 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Spring Bank Pharma in the fourth quarter valued at approximately $172,000. 29.17% of the stock is owned by hedge funds and other institutional investors.
About Spring Bank Pharma
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharma and related companies with MarketBeat.com's FREE daily email newsletter.